A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or - amplification or - mutation.

Trial Profile

A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or - amplification or - mutation.

Suspended
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Luminespib (Primary) ; Trastuzumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRY
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Mar 2016 Status changed from recruiting to suspended as per European Clinical Trials Database record.
    • 30 Sep 2014 Interim results in 5 patients presented at the 39th European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top